| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $47,527,516 ) (Continued on the next page) |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01MD017999 | Health equity in fertility specialty care among cancer survivors | 000 | 3 | NIH | 12/17/2024 | $447,420 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R03CA279867 | Calcium metabolism and lung cancer preneoplasia | 000 | 2 | NIH | 12/10/2024 | $81,000 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS101880 | Molecular Determinants of Synaptic Plasticity in Chronic Pain | 000 | 8 | NIH | 11/21/2024 | $451,854 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS119162 | New Therapeutic Approaches for Stratified High-REST GBM Subtype | 000 | 5 | NIH | 11/21/2024 | $364,500 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R34AT012360 | Randomized controlled trial to test feasibility of a culturally adapted meditation-based support intervention for Black patients dealing with advanced cancer | 001 | 3 | NIH | 12/19/2024 | $218,700 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA299696 | Decoding the co-evolution of cancer subclones and their ecosystem in TNBC multi-organ metastasis | 000 | 1 | NIH | 3/12/2025 | $676,584 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA295834 | Endogenous Circular RNAs limit abemaciclib anti tumor immune responses | 000 | 1 | NIH | 3/17/2025 | $567,059 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA251067 | Elucidating pro-metastatic collagen modifying activities of lysyl hydroxylase 2 | 000 | 5 | NIH | 3/12/2025 | $496,628 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01CA275886 | Identifying and targeting collateral lethal vulnerabilities in cancers | 001 | 3 | NIH | 3/12/2025 | $870,334 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS117668 | Systematic dissection of function and mechanism of long non-coding RNAs in glioblastoma | 000 | 5 | NIH | 3/12/2025 | $364,500 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | UG1CA233329 | UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAPS) UG1 | 000 | 6 | NIH | 3/12/2025 | $887,149 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA264992 | Establishing the clinical utility of a consensus DSC-MRI Protocol | 000 | 4 | NIH | 3/13/2025 | $500,546 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R03DE033550 | Probabilistic Deep Learning Cervical Lymph-Node Auto-Segmentation For Imaging-enhanced Evaluation of Extracapsular Extension Risk (PDL-CLASIFIER) | 000 | 2 | NIH | 3/18/2025 | $145,800 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | P40OD010938 | Squirrel Monkey Breeding and Research Resource | 002 | 44 | NIH | 3/18/2025 | $317,195 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA287279 | Deciphering the structural determinants of response and resistance to HER2-targeted antibody-drug conjugates and tyrosine kinase inhibitors for HER2-mutant Non-Small Cell Lung Cancer | 000 | 1 | NIH | 3/19/2025 | $695,004 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K99CA296940 | Adverse gut microbiome promotes resistance immune checkpoint inhibitors via chronic inflammation | 000 | 1 | NIH | 3/20/2025 | $32,400 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R03CA289563 | Effect of SIRPalpha mismatch on the outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) from an HLA matched related donor | 000 | 2 | NIH | 3/19/2025 | $81,000 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AT012375 | Multi-site feasibility and acceptability of a faith-based mind-body intervention in Black adults | 001 | 3 | NIH | 3/19/2025 | $0 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R00CA287069 | A Chemoproteomic Approach to Identify Molecular Glues for Targeted Cancer Therapy | 000 | 2 | NIH | 3/20/2025 | $224,100 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | T32CA009599 | Training of Academic Surgical Oncologists | 001 | 37 | NIH | 3/28/2025 | $782,693 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AI155582 | Neutrophil Extracellular Traps and Host Immunity | 000 | 5 | NIH | 3/28/2025 | $405,000 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AG071174 | Statistical Modeling of Alzheimer's Disease Progression Integrating Brain Imaging and -Omics Data | 000 | 6 | NIH | 3/20/2025 | $587,610 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K08CA263298 | Skin Cancer Risks and Risk Prediction in Patients with Actinic Keratosis | 000 | 4 | NIH | 3/19/2025 | $260,187 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS126252 | Regulation of Peripheral Neuropathic Pain by B Cells | 001 | 4 | NIH | 2/13/2025 | $484,813 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA202919 | Mechanistic basis and therapeutic strategies for ARID1A mutation in ovarian cancer | 000 | 10 | NIH | 1/9/2025 | $336,677 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA288804 | A Novel Strategy of Targeting Transmembrane Protein to Improve KRAS-targeted Therapy | 000 | 2 | NIH | 2/13/2025 | $170,405 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AT012375 | Multi-site feasibility and acceptability of a faith-based mind-body intervention in Black adults | 000 | 3 | NIH | 1/29/2025 | $497,585 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA286318 | Exploring new strategy for breast cancer immunoprevention by targeting histamine receptor H1 | 000 | 2 | NIH | 1/8/2025 | $170,405 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA269622 | An image-guided immunotherapy and hyperthermia delivery device to overcome barriers to tumor immunity for advanced hepatocellular carcinoma | 000 | 3 | NIH | 2/12/2025 | $417,797 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R34AT012360 | Randomized controlled trial to test feasibility of a culturally adapted meditation-based support intervention for Black patients dealing with advanced cancer | 002 | 3 | NIH | 1/9/2025 | $0 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA288827 | Deciphering the Critical Determinants of Enteric and Tumor Niche Colonization by Microbes in Colorectal Cancer | 000 | 1 | NIH | 1/15/2025 | $697,763 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS122143 | Analyzing the Endothelial Cell-Expressed Prion Gene Prnd in Vascular Development | 000 | 4 | NIH | 11/29/2024 | $360,856 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278938 | Comparative Effectiveness of Sequential Pharmacotherapeutic Strategies and Virtually Delivered Treatment to Optimize Smoking Cessation | 000 | 2 | NIH | 12/23/2024 | $819,991 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA299972 | Deregulation of Sulfatide Synthesis in the Development and Progression of Pancreatic Cancer Precursor Lesions | 000 | 1 | NIH | 3/1/2025 | $616,495 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA258788 | A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain | 000 | 4 | NIH | 2/14/2025 | $494,624 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA256848 | Determining the optimal ion and fractionation scheme for the treatment of GBM in a comprehensive human organoid model | 000 | 5 | NIH | 2/14/2025 | $412,116 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269489 | Molecular Mechanisms of Bladder Cancer Immunometabolism | 000 | 3 | NIH | 3/7/2025 | $444,485 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AG067419 | Alzheimer's Disease Pathology in a Primate Model | 000 | 5 | NIH | 2/14/2025 | $646,905 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA258917 | Mitochondrial heterogeneity as the origin of chemoresistance in pancreatic cancer | 000 | 5 | NIH | 3/7/2025 | $414,028 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01DE032168 | Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-Enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI) | 000 | 3 | NIH | 3/11/2025 | $634,331 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA236905 | Molecular Understanding and Targeting of Determinant Factors in Gastric Tumorigenesis | 000 | 5 | NIH | 3/3/2025 | $333,518 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | F30CA290816 | Evaluating Antigen Spread After cDC1 Vaccination | 000 | 1 | NIH | 3/10/2025 | $37,034 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA288901 | Proteomics-driven precision molecular mapping of patient tumors to preclinical models in lung cancer | 000 | 1 | NIH | 3/11/2025 | $244,228 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA262437 | ROLE OF SORD IN SUGAR-MEDIATED CANCER METASTASIS | 000 | 5 | NIH | 3/3/2025 | $324,064 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K99CA296780 | The role of oral microbiota in metastatic brain tumors | 000 | 1 | NIH | 3/10/2025 | $112,026 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA301555 | Delivery optimization of a transarterial ablative therapy | 000 | 1 | NIH | 3/11/2025 | $536,836 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21LM014699 | Novel designs for multi-arm multi-dose multi-stage platform trials | 001 | 1 | NIH | 3/11/2025 | $0 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA288448 | Mechanisms of Hyperprogression to Immunotherapy in SMARCB1-Deficient Renal Malignancies | 000 | 2 | NIH | 3/3/2025 | $605,071 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA258226 | Investigation of the role of epithelial-mesenchymal plasticity in renal cell carcinoma | 000 | 5 | NIH | 3/11/2025 | $567,599 |
|
